In metastatic NSCLC (stage IV), systemic therapies, including chemotherapy, immunotherapy, and targeted treatments, are guided by molecular profiling to identify actionable mutations such as Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) rearrangements or high PD-L1 expression [9,10]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.